KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Exchange Rate Effect (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Exchange Rate Effect data on record, last reported at -$209000.0 in Q4 2025.

  • For Q4 2025, Exchange Rate Effect rose 71.76% year-over-year to -$209000.0; the TTM value through Dec 2025 reached -$1.7 million, down 68.17%, while the annual FY2025 figure was -$1.7 million, 68.17% down from the prior year.
  • Exchange Rate Effect reached -$209000.0 in Q4 2025 per AMRX's latest filing, up from -$694000.0 in the prior quarter.
  • Across five years, Exchange Rate Effect topped out at $767000.0 in Q1 2023 and bottomed at -$3.7 million in Q4 2022.
  • Average Exchange Rate Effect over 5 years is -$409750.0, with a median of -$255000.0 recorded in 2023.
  • Peak YoY movement for Exchange Rate Effect: surged 148.79% in 2023, then tumbled 10014.29% in 2025.
  • A 5-year view of Exchange Rate Effect shows it stood at $178000.0 in 2021, then tumbled by 2200.56% to -$3.7 million in 2022, then skyrocketed by 105.38% to $201000.0 in 2023, then tumbled by 468.16% to -$740000.0 in 2024, then soared by 71.76% to -$209000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Exchange Rate Effect were -$209000.0 in Q4 2025, -$694000.0 in Q3 2025, and -$307000.0 in Q2 2025.